JOANNEUM RESEARCH MATERIALS’ Post

We’re attending #WCBP2025 this week! Kincell Bio’s Chief Technology Officer, Bruce Thompson, will be sharing his thoughts on how technology is revolutionizing the way small businesses operate—and what leaders need to do to stay ahead. Be sure to check out his Plenary Session 7 – Navigating the Small and Virtual Business Landscape: Managing More with Less on Thursday, January 30th at 8:30 EST. The cell therapy space is evolving rapidly, and many of the most groundbreaking advancements are coming from small biotech companies. Yet, these innovators face unique challenges—resource constraints, regulatory complexities, and the need for strategic partnerships to scale efficiently.   As a tech-savvy CDMO, we see firsthand how the right technology, expertise, and collaboration can accelerate development and manufacturing, helping these companies bridge the gap from concept to clinic. #CASSS #WCBP #CellTherapy

Reflecting on 2024: Advancing Science with New Technology at Labshares! This year, Labshares took major steps to support our members’ groundbreaking work by bringing more state-of-the-art equipment in-house. By investing in advanced tools, we’re providing our community with new opportunities to advance their research and innovation. Here’s a look at the new equipment we introduced in 2024: 🔬 MSD Technology 🔬 Cytek Aurora Flow Cytometer 🔬 BD FACS Melody Cell Sorter 🔬 Solentim VIPS Pro Single Cell Dispenser 🔬 Integra Assist Plus 🔬 Harvard Apparatus Gemini Electroporators 🔬 Thermo Fisher Veriti Pro PCR 🔬 Thermo Fisher Xenith Flow Cytometer These tools reflect our commitment to empowering our members to achieve more—whether it’s accelerating research, refining workflows, or achieving results faster than ever before. A heartfelt thank you to our members and team for helping make this milestone year a success. We’re proud to grow alongside your teams and look forward to what’s ahead in 2025! #Labshares #2024Highlights #CuttingEdgeTechnology #BiotechInnovation #ScientificAdvancements

🚨 miDiagnostics Secures €30M Series D Funding to Advance Sterility Testing for Biopharma! 🧬💡 Belgium-based MiDiagnostics has raised €30M in its Series D funding round, led by Thermo Fisher Scientific and supported by existing investors like Alychlo, VMF Invest, and Pamica. With this new funding, MiDiagnostics will: 🔬 Accelerate development of a revolutionary sterility test for batch release in biopharma using its cutting-edge qPCR technology. 🌍 Leverage Thermo Fisher’s expertise to bring innovative solutions to market. 💻 MiDiagnostics’ tech combines: ✔️ A nanofluidic processor on a silicon chip ✔️ A compact reader for rapid analyte measurement MiDiagnostics CEO Katleen Verleysen stated: "This funding will enable us to expedite our development efforts and revolutionize sterility testing in the biopharma sector.” Notably, MiDiagnostics is also behind a SARS-CoV-2 breath test developed in 2021, showcasing its commitment to pushing boundaries in diagnostics. 🔗 Collaborations with imec and The Johns Hopkins University highlight the firm’s strong foundation in innovation. #Diagnostics #Biopharma #FundingNews #Innovation #ThermoFisher #LifeSciences #MiDiagnostics #PCRTechnology

Unlocking the Potential of Small Molecules in Drug Development MedChemTronica's small molecules are transforming drug development with their cell penetration, oral bioavailability, and reproducible manufacturing. These versatile compounds target a broad spectrum of diseases and conditions, offering precision and efficiency in drug design. With advancements like molecular glues, AI-assisted design, and PROTACs, small molecules continue to lead innovation in modern medicine. ✨ Explore their impact in our latest blog:https://hubs.la/Q0300Prb0 #SmallMolecules #DrugDiscovery #MedChemTronica #NordicBiosite

We’re pleased to release our fifth and final video in collaboration with FLUIDDA. In this concluding instalment, Dr. Will Ganley (Nanopharm) and Dr. Jan De Backer (FLUIDDA) speak to Dr Eleanor Canipa and share their expert insights into the OINDP space and dive into the transformative potential of Nanopharm’s SmartTrack™ programme. Watch the video now to learn how innovation is shaping the future of inhalation science. Have you enjoyed the series and want to connect with us? Reach out at info@nanopharm.co.uk— we’d love to hear from you! #Innovation #FiresideSeries #OINDP #SmartTrack #InhalationScience #Nanopharm

We are thrilled and proud to host six exceptional Israeli companies in our lounge during the JPM Conference! If you intend to be in San Francisco during Jan 13-15, 2025, this is an incredible opportunity to connect with some of Israel's most innovative and forward-thinking companies. We encourage investors and strategic partners to schedule a meeting with these dynamic businesses to explore potential collaborations, investments, and partnerships. Don’t miss the chance to engage with the companies that are shaping the future across various industries. Innosphere Nano24 Neteera OphtiMed Rx PhaseV PregnanTech Let’s create new opportunities and drive impactful growth together! To learn more about these companies, and schedule a meeting, check the comments below ⬇️ #jpmc25 #medtech #healthinnovation #pharma #investmentopportunity

Here is how to take your business to the next level with grant funding... Since 2007 BioSensics, has leveraged government funding to meet—and exceed—their business goals. Here’s how they did it, and what you can learn from their success: 1. Early-Stage Support – BioSensics secured their first STTR award in 2009, which fueled their R&D efforts in aging and neurological disorders. 2. Product Refinement – The SBIR/STTR review process provided more than capital; it gave them invaluable feedback that shaped their advanced medical alert solutions. 3. Strategic Commercialization – By developing FDA-registered devices and licensing their technology, BioSensics used grant funding to take their products to market through partners like Best Buy and Mytrex, ensuring widespread adoption. 4. Market Expansion – In 2018, BioSensics used their grant-funded R&D to launch a clinical trial business, partnering with pharmaceutical giants to transform the use of wearable sensors in trials. BioSensics’ story is a blueprint for how businesses can harness the power of grants to fuel innovation, enter new markets, and drive growth. What’s been your experience with grant funding? Share your thoughts below! 👉 Learn more about BioSensics: www.biosensics.com #GrantFunding #SBIR #STTR #BusinessGrowth #HealthcareInnovation #WearableTech

CORLINE BIOMEDICAL AB provides antithrombotic and anti-inflammatory surface coating solutions to customers in the medical device industry and the rapidly advancing field of regenerative medicine. Utilizing proprietary heparin technology, Corline offers its industry-leading antithrombotic coating – the Corline Heparin Surface (CHS™) – to medical device manufacturers. Building on the same technology platform, Renaparin® is tailored for the regenerative medicine sector, enhancing the functionality and safety of customers' products. The manufacturing of reagents and surface coating services is conducted at Corline's state-of-the-art cleanroom facilities in Uppsala, Sweden. The company's shares (CLBIO) are listed on the Nasdaq First North Growth Market in Stockholm.

CannaMetrix’s innovative EC50 Array™ technology accurately captures the complex interactions between #cannabinoids and the #humanbody, providing insight into a product's true #potency and therapeutic benefits. Read the original research: https://bit.ly/4e8swsX

#ausbiotech2024 #medicaldevices #CE #ISO13485 #mdsap Come chat with us towards your device journey into global market #commercialisation